Thomas Kelly serves as Chief Financial Officer at XENON PHARMACEUTICALS INC., a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological disorders. With over 25 years of experience in the biotechnology and pharmaceutical sectors, Kelly began his career at Deloitte & Touche, where he specialized in audit services for life sciences clients. He later held progressive finance leadership roles at companies such as Genentech and Amgen, managing global financial operations, investor relations, and strategic planning during periods of rapid growth and clinical pipeline expansion. Kelly's notable achievements include spearheading a $200 million equity financing round at a previous biotech firm, which funded Phase III trials and led to a successful FDA approval. He has also orchestrated multiple mergers and acquisitions, including a $500 million cross-border transaction that enhanced operational efficiencies and expanded market reach. Under his guidance, organizations have consistently achieved strong financial performance, with improvements in cash flow management and compliance with SEC reporting standards. At XENON PHARMACEUTICALS INC., Kelly oversees all financial aspects, including budgeting, forecasting, treasury management, and capital raising to support the company's pipeline of epilepsy and other neurology treatments. His strategic foresight has been instrumental in navigating market volatility, securing non-dilutive funding from government grants, and positioning the company for potential partnerships and commercialization milestones. Kelly holds an MBA from the Wharton School and a Bachelor's degree in Accounting from the University of Pennsylvania.